YTYuichi Takahashi

Yuichi Takahashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuichi Takahashi has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Yutaka Kanda

    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi, Sunto, Shizuoka, Japan

    3 shared publications
  • Mayumi Yoshida

    Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd, 3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533, Japan

    2 shared publications
  • Rieko Tanaka

    Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd, 3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533, Japan

    2 shared publications
  • Akihiro Senoo

    Bioprocess Development Center, Kyowa Hakko Bio Co., Ltd., 2 Miyukigaoka, Tsukuba‐shi, Ibaraki 305‐0841, Japan

    1 shared publication
  • Akira Asai

    Center for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

    1 shared publication
  • Atsushi Noguchi

    Department of Internal Medicine, Japanese Red Cross Kitami Hospital, Kitami, Japan

    1 shared publication

Latest Publications

  • The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase

    by Ryoko Okada-Iwasaki, Yuichi Takahashi, Yasuo Watanabe, Hiroshi Ishida, Jun-Ichi Saito, Ryuichiro Nakai, Akira Asai

    The Wnt/β-catenin pathway is a well-known oncogenic pathway. Its suppression has long been considered as an important challenge in treating cancer patients. Among colon cancer patients in particular, most patients carry an adenomatous polyposis coli (APC) mutation that leads to an aberration of Wnt/β-catenin pathway. To discover the small molecule inhibitors of the Wnt/β-catenin pathway, we conducted high-throughput screening in APC-mutant colon cancer DLD-1 cells using a transcriptional reporter assay, which identified a selective Wnt/β-catenin pathway inhibitor, K-756. K-756 stabilizes Axin and reduces active β-catenin, and inhibits the genes downstream of endogenous Wnt/β-catenin. We subsequently identified that K-756 is a tankyrase (TNKS) inhibitor. TNKS, which belongs to the PARP family, poly-ADP ribosylates Axin and promotes Axin degradation via the proteasome pathway. K-756 binds to the induced pocket of TNKS and inhibits its enzyme activity. Moreover, PARP family enzyme assays showed that K-756 is a selective TNKS inhibitor. K-756 inhibited the cell growth of APC-mutant colorectal cancer COLO 320DM and SW403 cells by inhibiting the Wnt/β-catenin pathway. An in vivo study showed that the oral administration of K-756 inhibited the Wnt/β-catenin pathway in colon cancer xenografts in mice. To further explore the therapeutic potential of K-756, we also evaluated the effects of K-756 in non–small cell lung cancer cells. Although a single treatment of K-756 did not induce antiproliferative activity, when K-756 was combined with an EGFR inhibitor (gefitinib), it showed a strong synergistic effect. Therefore, K-756, a novel selective TNKS inhibitor, could be a leading compound in the development of anticancer agents. Mol Cancer Ther; 15(7); 1525–34. ©2016 AACR.


  • The structure ofL-amino-acid ligase fromBacillus licheniformis

    by Michihiko Suzuki, Yuichi Takahashi, Atsushi Noguchi, Toshinobu Arai, Makoto Yagasaki, Kuniki Kino, Jun-Ichi Saito

    L-Amino-acid ligases (LALs) are enzymes which catalyze the formation of dipeptides by linking two L-amino acids. Although many dipeptides are known and expected to have medical and nutritional benefits, their practical use has been limited owing to their low availability and high expense. LALs are potentially desirable tools for the efficient production of dipeptides; however, the molecular basis of substrate recognition by LAL has not yet been sufficiently elucidated for the design of ideal LALs for the desired dipeptides. This report presents the crystal structure of the LAL BL00235 derived fromBacillus licheniformisNBRC 12200 determined at 1.9 Å resolution using the multi-wavelength anomalous dispersion method. The overall structure of BL00235 is fairly similar to that of YwfE, the only LAL with a known structure, but the structure around the catalytic site contains some significant differences. Detailed structural comparison of BL00235 with YwfE sheds some light on the molecular basis of the substrate specificities.


  • Open Access

    Structural and enzymatic characterization of BacD, an L‐amino acid dipeptide ligase from Bacillus subtilis

    by Yasuhito Shomura, Emi Hinokuchi, Hajime Ikeda, Akihiro Senoo, Yuichi Takahashi, Jun‐Ichi Saito, Hirofumi Komori, Naoki Shibata, Yoshiyuki Yonetani, Yoshiki Higuchi

    BacD is an ATP‐dependent dipeptide ligase responsible for the biosynthesis of L‐alanyl‐L‐anticapsin, a precursor of an antibiotic produced by Bacillus spp. In contrast to the well‐studied and phylogenetically related D‐alanine: D‐alanine ligase (Ddl), BacD synthesizes dipeptides using L‐amino acids as substrates and has a low substrate specificity in vitro. The enzyme is of great interest because of its potential application in industrial protein engineering for the environmentally friendly biological production of useful peptide compounds, such as physiologically active peptides, artificial sweeteners and antibiotics, but the determinants of its substrate specificity and its catalytic mechanism have not yet been established due to a lack of structural information. In this study, we report the crystal structure of BacD in complex with ADP and an intermediate analog, phosphorylated phosphinate L‐alanyl‐L‐phenylalanine, refined to 2.5‐Å resolution. The complex structure reveals that ADP and two magnesium ions bind in a manner similar to that of Ddl. However, the dipeptide orientation is reversed, and, concomitantly, the entrance to the amino acid binding cavity differs in position. Enzymatic characterization of two mutants, Y265F and S185A, demonstrates that these conserved residues are not catalytic residues at least in the reaction where L‐phenylalanine is used as a substrate. On the basis of the biochemical and the structural data, we propose a reaction scheme and a catalytic mechanism for BacD.


  • Conformational significance of EH21A1–A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity

    by Hideyuki Onodera, Masami Kaneko, Yuichi Takahashi, Yumiko Uochi, Jun Funahashi, Takayuki Nakashima, Shiro Soga, Makoto Suzuki, Shunichi Ikeda, Yoshinori Yamashita, et al.


  • Structure elucidation of EI-1941-1 and -2, novel interleukin-1β converting enzyme inhibitors produced by Farrowia sp. E-1941

    by Fumito Koizumi, Yuichi Takahashi, Hiroki Ishiguro, Rieko Tanaka, Shizuo Ohtaki, Mayumi Yoshida, Satoshi Nakanishi, Shun-Ichi Ikeda


  • Discovery and Structure−Activity Relationships of Novel Piperidine Inhibitors of Farnesyltransferase

    by Shinji Nara, Rieko Tanaka, Jun Eishima, Mitsunobu Hara, Yuichi Takahashi, Shizuo Otaki, Robert J. Foglesong, Philip F. Hughes, Shelley Turkington, Yutaka Kanda

    A novel piperidine series of farnesyltransferase (FTase) inhibitors is described. Systematic medicinal chemistry studies starting with the lead compound, discovered from a 5-nitropiperidin-2-one combinatorial library, resulted in a potent series of novel FTase inhibitors. We found that all of four substituents of the piperidine core played an important role for FTase inhibition. A 10-fold increase in potency was observed by changing the piperidine-2-one core to the corresponding piperidine core. This class of compounds was found to inhibit farnesyltransferase in a Ras competitive manner. Optical resolution of several potent inhibitors revealed that the (+)-enantiomers showed potent farnesyltransferase inhibition. (+)-8 inhibited FTase with an IC50 of 1.9 nM.


  • Synthesis and Antitumor Activity of Novel Thioester Derivatives of Leinamycin

    by Yutaka Kanda, Tadashi Ashizawa, Shingo Kakita, Yuichi Takahashi, Motomichi Kono, Mayumi Yoshida, Yutaka Saitoh, Masami Okabe